Swiss drug developer Windward Bio Group targets a $1 billion valuation in its US IPO, raising $185.3 million for antibody medicines treating respiratory and dermatologic diseases. The offering is back
reuters · 2026-11-09 04:09
Sanofi raised its annual sales growth forecast to a low-teens percentage, driven by strong demand for Dupixent. The company also announced plans for potential M&A deals exceeding €5 billion to secure
reuters · 2026-10-29 23:59
Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones to expand their immunology antibody partnership, including Dupixent. The deal settles litigation, splitting costs and p
reuters · 2026-09-30 22:17
Sanofi exceeded first-quarter earnings expectations with a 30.8% surge in Dupixent sales, while preparing for CEO Belén Garijo to take over in April after Paul Hudson's departure.
reuters · 2026-04-22 22:35